drug_type
RELEVANT_DRUG
intervention_type
biologic (bispecific monoclonal antibody, T-cell engager)
drug_description
An intravenous T-cell–engaging bispecific monoclonal antibody that binds CD3 on T cells and FcRH5/FCRL5 on myeloma cells to redirect T-cell cytotoxicity.
nci_thesaurus_concept_id
C139549
nci_thesaurus_preferred_term
Cevostamab
nci_thesaurus_definition
A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Cevostamab is an intravenous bispecific monoclonal antibody that simultaneously binds CD3 on T cells and FcRH5 (FCRL5) on myeloma cells, physically bridging T cells to FcRH5-expressing plasma cells. This crosslinking activates TCR/CD3 signaling, triggers cytokine release, and drives perforin/granzyme-mediated cytotoxicity leading to targeted lysis of FcRH5+ tumor cells.
drug_name
Cevostamab
nct_id_drug_ref
NCT05801939